SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
(SRNE) IJME publication of QUELIMMUNE therapy for pediatric AKI shows a potential for hospitals to incur no out-of-pocket costs for 6 days of treatment.